Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Developments in virus-like particle-based vaccines for infectious diseases and cancer.

Buonaguro L, Tagliamonte M, Tornesello ML, Buonaguro FM.

Expert Rev Vaccines. 2011 Nov;10(11):1569-83. doi: 10.1586/erv.11.135. Review.

PMID:
22043956
2.

Developments in virus-like particle-based vaccines for HIV.

Buonaguro L, Tagliamonte M, Visciano ML, Tornesello ML, Buonaguro FM.

Expert Rev Vaccines. 2013 Feb;12(2):119-27. doi: 10.1586/erv.12.152. Review.

PMID:
23414404
3.

MHC class II-associated invariant chain linkage of antigen dramatically improves cell-mediated immunity induced by adenovirus vaccines.

Holst PJ, Sorensen MR, Mandrup Jensen CM, Orskov C, Thomsen AR, Christensen JP.

J Immunol. 2008 Mar 1;180(5):3339-46.

4.

Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy.

Bonehill A, Heirman C, Thielemans K.

J Gene Med. 2005 Jun;7(6):686-95. Review.

PMID:
15693037
5.

T-cell immunity generated by recombinant adenovirus vaccines.

Yang TC, Millar JB, Grinshtein N, Bassett J, Finn J, Bramson JL.

Expert Rev Vaccines. 2007 Jun;6(3):347-56. Review.

PMID:
17542750
6.

Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses.

Báez-Astúa A, Herráez-Hernández E, Garbi N, Pasolli HA, Juárez V, Zur Hausen H, Cid-Arregui A.

J Virol. 2005 Oct;79(20):12807-17.

8.

Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response.

Flanagan K, Glover RT, Hörig H, Yang W, Kaufman HL.

Vaccine. 2004 Jul 29;22(21-22):2894-903.

PMID:
15246626
9.

A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4⁺ and CD8⁺ T-cell as well as B-cell responses.

Neumann F, Kubuschok B, Ertan K, Schormann C, Stevanovic S, Preuss KD, Schmidt W, Pfreundschuh M.

Cancer Immunol Immunother. 2011 Sep;60(9):1333-46. doi: 10.1007/s00262-011-1030-6. Epub 2011 Jun 1.

PMID:
21630107
10.

Virus-like particles as particulate vaccines.

Buonaguro L, Tornesello ML, Buonaguro FM.

Curr HIV Res. 2010 Jun;8(4):299-309. Review.

PMID:
20353398
11.

MHC class I TCR engineered anti-tumor CD4 T cells: implications for cancer immunotherapy.

Chhabra A.

Endocr Metab Immune Disord Drug Targets. 2009 Dec;9(4):344-52.

PMID:
19807670
12.

Expression of a foreign epitope on infectious pancreatic necrosis virus VP2 capsid protein subviral particle (SVP) and immunogenicity in rainbow trout.

Dhar AK, Bowers RM, Rowe CG, Allnutt FC.

Antiviral Res. 2010 Mar;85(3):525-31. doi: 10.1016/j.antiviral.2009.12.009. Epub 2010 Jan 9.

PMID:
20060858
13.

Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.

Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Löwik MJ, Berends-van der Meer DM, Drijfhout JW, Valentijn AR, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, Melief CJ, van der Burg SH.

Clin Cancer Res. 2008 Jan 1;14(1):178-87. doi: 10.1158/1078-0432.CCR-07-1880.

14.

MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.

Ilkovitch D, Ostrand-Rosenberg S.

Cancer Immunol Immunother. 2004 Jun;53(6):525-32. Epub 2004 Jan 17.

PMID:
14730400
15.

Assessment of human CD4+ and CD8+ T lymphocyte responses in experimental viral vaccine studies.

Rothman AL, Yamada Y, Jameson J, Cruz J, West K, Green S, Ennis FA.

Dev Biol Stand. 1998;95:95-104. Review.

PMID:
9855419
16.
17.
18.
19.

Virus-like particles as vaccine adjuvants.

Gilbert SC.

Mol Biotechnol. 2001 Oct;19(2):169-77.

PMID:
11725486

Supplemental Content

Support Center